Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ipsen SA
Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.
Adding to its liver disease portfolio, Gilead agreed to pay a 27% premium for CymaBay and seladelpar, which has a 14 August FDA action date to compete in second-line primary biliary cholangitis.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Clementia Pharmaceuticals, Inc.
- Epizyme, Inc.
- Ipsen Bioscience, Inc.
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.